Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MTNR1A | P48039 | 6/20 | 0.73 |
| ▸ | MTNR1B | P49286 | 6/20 | 0.73 |
| ▸ | GRIN2B | Q13224 | 5/20 | 0.54 |
| ▸ | CA1 | P00915 | 1/20 | 0.54 |
| ▸ | CA2 | P00918 | 1/20 | 0.54 |
| ▸ | MAOA | P21397 | 1/20 | 0.53 |
| ▸ | MAOB | P27338 | 1/20 | 0.53 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.49 |
| ▸ | GRM7 | Q14831 | 2/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30612411 | 1.00 | MTNR1A (0.73) | MTNR1AMTNR1BGRIN2BCA1CA2 | |
| SCHEMBL9851524 | 0.87 | GRM7 (0.59) | MTNR1AMTNR1BCA1CA2GRM7 | |
| SCHEMBL9731843 | 0.85 | MTNR1A (0.67) | MTNR1AMTNR1BGRIN2BCA1CA2 | |
| SCHEMBL1970411 | 0.84 | MTNR1A (1.00) | MTNR1AMTNR1BGRIN2BCA1CA2 | |
| SCHEMBL1970413 | 0.84 | MTNR1A (1.00) | MTNR1AMTNR1BGRIN2BCA1CA2 | |
| SCHEMBL3897095 | 0.84 | MTNR1A (0.71) | MTNR1AMTNR1BGRIN2BCA1CA2 | |
| SCHEMBL26763719 | 0.80 | MTNR1A (0.69) | MTNR1AMTNR1BCA1CA2MAOA | |
| SCHEMBL2597383 | 0.80 | MTNR1A (1.00) | MTNR1AMTNR1BMAOAMAOB | |
| SCHEMBL827706 | 0.80 | MTNR1A (1.00) | MTNR1AMTNR1BMAOAMAOB | |
| SCHEMBL433099 | 0.80 | CA1 (0.70) | MTNR1AMTNR1BGRIN2BCA1CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11312668-B2 | Organic reactions carried out in aqueous solution in the presence of a hydroxyalkyl(alkyl)cellulose or an alkylcellulose | ABBVIE INC. (US) | 2022-04-26 | — | — | US | disclosed |
| US-20210017100-A1 | ORGANIC REACTIONS CARRIED OUT IN AQUEOUS SOLUTION IN THE PRESENCE OF A HYDROXYALKYL(ALKYL)CELLULOSE OR AN ALKYLCELLULOSE | AbbVie Deutschland GmbH & Co. KG (DE) | 2021-01-21 | — | — | US | disclosed |
| US-10836688-B2 | Organic reactions carried out in aqueous solution in the presence of a hydroxyalkyl(alkyl)cellulose or an alkylcellulose | ABBVIE INC. (US) | 2020-11-17 | — | — | US | disclosed |
| EP-3408258-B1 | ORGANIC REACTIONS CARRIED OUT IN AQUEOUS SOLUTION IN THE PRESENCE OF A HYDROXYALKYL(ALKYL)CELLULOSE OR AN ALKYLCELLULOSE | ABBVIE DEUTSCHLAND (DE) | 2020-07-01 | — | — | EP | disclosed |
| US-20200148610-A1 | ORGANIC REACTIONS CARRIED OUT IN AQUEOUS SOLUTION IN THE PRESENCE OF A HYDROXYALKYL(ALKYL)CELLULOSE OR AN ALKYLCELLULOSE | ABBVIE INC. | 2020-05-14 | — | — | US | disclosed |
| EP-3408258-A1 | ORGANIC REACTIONS CARRIED OUT IN AQUEOUS SOLUTION IN THE PRESENCE OF A HYDROXYALKYL(ALKYL)CELLULOSE OR AN ALKYLCELLULOSE | Abbvie Deutschland GmbH & Co. KG (DE) | 2018-12-05 | — | — | EP | disclosed |
| US-20170217850-A1 | ORGANIC REACTIONS CARRIED OUT IN AQUEOUS SOLUTION IN THE PRESENCE OF A HYDROXYALKYL(ALKYL)CELLULOSE OR AN ALKYLCELLULOSE | ABBVIE INC. | 2017-08-03 | — | — | US | disclosed |
| WO-2017129796-A1 | ORGANIC REACTIONS CARRIED OUT IN AQUEOUS SOLUTION IN THE PRESENCE OF A HYDROXYALKYL(ALKYL)CELLULOSE OR AN ALKYLCELLULOSE | AbbVie Deutschland GmbH & Co. KG (DE) | 2017-08-03 | — | — | WO | disclosed |
| EP-2888225-A1 | ARYLALKYLAMINE COMPOUNDS AS CALCIUM SENSING RECEPTOR MODULATORS | Lupin Limited (IN) | 2015-07-01 | — | — | EP | disclosed |
| WO-2014033604-A1 | ARYLALKYLAMINE COMPOUNDS AS CALCIUM SENSING RECEPTOR MODULATORS | LUPIN LIMITED (IN) | 2014-03-06 | — | — | WO | disclosed |
| US-8513235-B2 | Homocysteine synthase inhibitor | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2013-08-20 | — | — | US | disclosed |
| EP-2486925-A1 | THERAPEUTIC AGENT FOR CEREBRAL INFARCTION | Mitsubishi Tanabe Pharma Corporation (JP) | 2012-08-15 | — | — | EP | disclosed |
| US-20120196824-A1 | THERAPEUTIC AGENT FOR CEREBRAL INFARCTION | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2012-08-02 | — | — | US | disclosed |
| EP-0447292-A1 | 4-Aminomethyl-piperidine derivatives, their preparation and therapeutic application | SYNTHELABO (FR) | 1991-09-18 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210017100-A1 | ORGANIC REACTIONS CARRIED OUT IN AQUEOUS SOLUTION IN THE PRESENCE OF A HYDROXYALKYL(ALKYL)CELLULOSE OR AN ALKYLCELLULOSE | LIPA, ALG1, CEL | MTNR1A 4854/4885MTNR1B 4786/4885GRIN2B 4825/4885 |
| US-20200148610-A1 | ORGANIC REACTIONS CARRIED OUT IN AQUEOUS SOLUTION IN THE PRESENCE OF A HYDROXYALKYL(ALKYL)CELLULOSE OR AN ALKYLCELLULOSE | LIPA, ALG1, CEL | MTNR1A 4854/4885MTNR1B 4786/4885GRIN2B 4825/4885 |
| US-20120196824-A1 | THERAPEUTIC AGENT FOR CEREBRAL INFARCTION | FABP7, TIMP3, MMP11 | MTNR1A 108/4885MTNR1B 240/4885GRIN2B 959/4885 |
| US-10836688-B2 | Organic reactions carried out in aqueous solution in the presence of a hydroxyalkyl(alkyl)cellulose or an alkylcellulose | LIPA, ALG1, CEL | MTNR1A 4854/4885MTNR1B 4786/4885GRIN2B 4825/4885 |
| US-20170217850-A1 | ORGANIC REACTIONS CARRIED OUT IN AQUEOUS SOLUTION IN THE PRESENCE OF A HYDROXYALKYL(ALKYL)CELLULOSE OR AN ALKYLCELLULOSE | LIPA, ALG1, CEL | MTNR1A 4854/4885MTNR1B 4786/4885GRIN2B 4825/4885 |
| US-11312668-B2 | Organic reactions carried out in aqueous solution in the presence of a hydroxyalkyl(alkyl)cellulose or an alkylcellulose | LIPA, ALG1, CEL | MTNR1A 4854/4885MTNR1B 4786/4885GRIN2B 4825/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.